NYXH
Nyxoah S.A.
There isn't enough reported data to score NYXH yet.
NYXH Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
NYXH's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
NYXH PE Valuation
NYXH has no meaningful PE right now: it lost money over the past year.
NYXH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect NYXH's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
NYXH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$2.41 | -$0.07 |
| Q1 2026 | -$2.38 | -$0.17 |
| Q4 2025 | -$2.63 | -$0.62 |
| Q3 2025 | -$2.49 | -$0.57 |
| Q2 2025 | -$2.34 | -$0.67 |
| Q1 2025 | -$2.21 | -$0.52 |
| Q4 2024 | -$2.01 | -$0.28 |
| Q3 2024 | -$1.92 | -$0.04 |
NYXH lost $2.41 per share over the past year, about the same as its loss the year before.
NYXH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $8.5M | +473% |
| Q1 2026 | $8.2M | +592% |
| Q4 2025 | $6.3M | +347% |
| Q3 2025 | $2.2M | +56% |
| Q2 2025 | $1.5M | +74% |
| Q1 2025 | $1.2M | -13% |
| Q4 2024 | $1.4M | -31% |
| Q3 2024 | $1.4M | +30% |
NYXH's revenue has grown year over year for five quarters in a row: $9M last quarter, up 473% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -268% | +1213 points |
| Q1 2026 | -322% | +1617 points |
| Q4 2025 | -324% | +1126 points |
| Q3 2025 | -1227% | -44 points |
| Q2 2025 | -1481% | +245 points |
| Q1 2025 | -1940% | -940 points |
| Q4 2024 | -1450% | -856 points |
| Q3 2024 | -1183% | -58 points |
NYXH's operating margin was −268% last quarter, up 1213 points from the same quarter a year ago, near the top of its range since 2020.
NYXH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$19.8M | -$639.9K |
| Q1 2026 | -$24.8M | -$4M |
| Q4 2025 | -$14.6M | +$682K |
| Q3 2025 | -$22.8M | -$7M |
| Q2 2025 | -$19.2M | -$5.2M |
| Q1 2025 | -$20.8M | -$4.5M |
| Q4 2024 | -$15.3M | -$369.9K |
| Q3 2024 | -$15.8M | -$40K |
NYXH has burned cash in almost every quarter: −$82M over the past year, against −$71M the year before.
NYXH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +32% | +13.8M shares |
| 1 year | +52% | +19.6M shares |
| 3 years | +99% | +28.4M shares |
| 5 years | +158% | +34.9M shares |
| Available history | +376% | +45M shares |
NYXH has 57M diluted shares, up 52% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
NYXH hasn't bought back shares in the past year.
NYXH Net Leverage
NYXH's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NYXH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.6 | Oversold |
| Stochastic | 6.9 | Oversold |
NYXH's weekly RSI is 27 (oversold) and its Stochastic is 7 (oversold).
NYXH PE vs Healthcare Sector
NYXH has no meaningful PE right now: it lost money over the past year.
NYXH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.09 | 17% below |
| 20 week MA | $1.37 | 34% below |
| 50 week MA | $2.70 | 67% below |
| 100 week MA | $5.04 | 82% below |
| 200 week MA | $6.61 | 86% below |
NYXH is in a downtrend: it's below all five of its weekly moving averages, and 86% below its 200-week average.
NYXH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.0 | $21.0 | -12% |
| 2022 | $21.0 | $5.20 | -75% |
| 2023 | $5.20 | $4.64 | -11% |
| 2024 | $4.64 | $8.00 | +72% |
| 2025 | $8.00 | $4.47 | -44% |
| 2026 YTD | $4.47 | $0.90 | -80% |
NYXH has finished lower in four of the last five years. It's down 80% so far in 2026.